UK pharma sector stays immune to Brexit as innovation, scale spur deals
Sector being propelled in part by weaker pound and need to keep pipelines supplied with new, lucrative treatments
London
AS the United Kingdom's vote to leave the European Union wreaks havoc on the British economy, dealmaking momentum in the country's pharmaceutical industry is showing no signs of letting up.
Healthcare acquisitions in the UK have risen 21 per cent this year as total mergers and acquisitions (M&A) fell 43 per cent in Britain and dropped 16 per cent worldwide, according to data compiled by Bloomberg.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Holiday Inn owner IHG’s Q1 revenue up 2.6%, leisure travel demand remains strong
WSJ moves Asia headquarters from Hong Kong to Singapore
South Korea to slap fines on food suppliers for ‘shrinkflation’
Olam outbids Dreyfus’ sweetened deal for Australia’s Namoi, raises offer to A$0.66 per share
Live Nation’s revenue beats estimates as boom in concerts drive ticket sales
Jim Beam owner bets on canned vodka cocktails to double revenue